`
`e
`
`
`~ Finish 4,5-methane SAR "holes"
`- Complete compelling inhibitersefrom DOCK run
`- Generate biclic 2,1,1 series
`
`V
`
`I"
`
`'
`
`
`
`12!'I6r?7
` J?7 M
`&
`
`/
`
`x
`
`Dave ME.
`
`ppgkash
`
`»- Syethesize Novartis clinical candldafe for Er: vitro! in viva evaluatlen
`- Synthesize Ferring Research lnstltute DP4 (lte—cyanopyrrolidide) for i°K1in
`vitro determination
`
`Dave A_
`
`wwork out 3,4—methane synthesis
`~ Scale-up 680 for PK determination
`w Build 3,4—-methane SAR
`
`Dave :3.
`
`—
`
`— Finish HIVEGR targeflss)
`— Build 3,4-methane SAR
`- Generate novel amino acids for N-terminus
`
`Gaya
`
`- Generate exopreyline series.
`~ Generate novel amino acids for N-terminus
`
`SAR "holes" with existing A965: phenylglycine, alanine, proline, 2-3 N-alkiated ANS, DOCK hits
`
`"Novel" N—terminai amine acids for incorporation:
`
`<’m§>
`\
`T Me
`it
`
`5“?
`KW
`1
`
`Me
`
`A
`V‘
`Me
`1. me
`it 7:
`
`Me “ET”
`‘+
`
`""‘*"‘e*“”°
`\k.
`
`“"32
`«Y;
`
`‘—.f\./‘-
`
`— X?
`5
`A L’; Q
`
`\.»"\x“
`
`u"v"
`
`3
`
`‘
`
`"
`
`l:cFa
`
`4%“
`
`»x*v‘-
`
`*2?‘
`
`u/xx‘
`
`‘
`
`g3kF\j“:}}.,1;s1;;l€r5;k
`
`s Umgfirfiiiwl‘
`K7»
`
`Y
`
`Page 1 of 1
`
`Astraleneca Exhibit 2187
`Mylan V. Astraleneca
`IPR2015-013-ll}
`
`AstraZeneca Exhibit 2187
`Mylan v. AstraZeneca
`IPR2015-01340
`
`Page 1 of 1